By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Indivumed and Apceth today announced a partnership to develop technology that can predict patient response to targeted cellular or gene therapies in different cancer types.

The technology, which would allow patients to be stratified based on their response to therapies, would use Indivumed's analytical platform for cancer tissue in order to identify and validate protein biomarkers and targets.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The World Health Organization calls for the public release of clinical trial results within a year of the completion of data collection.

In Science this week: measles virus nucleocapsid structure, and more.

African and US health officials work to establish an Africa-wide Centres for Disease Control and Prevention.

Nature has retracted a 2002 epigenetics paper for image manipulation.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.